Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, 1 Xinmin Street, Changchun, 130021, PR China.
Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 4, Section 2, Jianshe North Road, Chengdu, 610072, PR China.
Biomaterials. 2021 Mar;270:120680. doi: 10.1016/j.biomaterials.2021.120680. Epub 2021 Jan 22.
Pancreatic cancer (PC) is one kind of the most lethal malignancies worldwide, owing to its insidious symptoms, early metastases, and negative responses to current therapies. With an increasing understanding of pathology, the tumor microenvironment (TME) plays a significant role in ineffective treatment and poor prognosis of PC. Thus, a growing number of studies have focused on whether components of the TME could be effective targets for PC therapy. Biomaterials have been widely applied in cancer therapy, and numerous organic or inorganic biomaterials for TME regulation have been developed to inhibit the growth and metastasis of PC, as well as reverse therapeutic resistance. In this review, we discuss various biomaterials utilized to treat PC based on different components of the TME, including, but not limited to, extracellular matrix (ECM), abnormal tumor vascularization, and tumor-associated immune cells, as well as other unconventional therapeutic strategies. Besides, the perspectives on the underlying future of theranostic nanomedicines for PC therapy are also presented.
胰腺癌（PC）是全球最致命的恶性肿瘤之一，其症状隐匿、早期转移以及对现有治疗方法的负面反应是导致这一结果的主要原因。随着对病理学认识的不断深入，肿瘤微环境（TME）在 PC 治疗效果不佳和预后不良方面发挥着重要作用。因此，越来越多的研究关注 TME 的成分是否可以成为 PC 治疗的有效靶点。生物材料已广泛应用于癌症治疗，为了抑制 PC 的生长和转移，以及逆转治疗耐药性，已经开发出许多用于调节 TME 的有机或无机生物材料。在本文中，我们讨论了基于 TME 的不同成分（包括但不限于细胞外基质（ECM）、异常肿瘤血管生成和肿瘤相关免疫细胞）利用各种生物材料治疗 PC 的情况，以及其他非传统的治疗策略。此外，我们还对 PC 治疗的诊断-治疗一体化纳米医学的未来发展前景进行了展望。
